Drug-induced liver injury: Pattern recognition and future directions

Gut and Liver

Volumn 10, Issue 1, 2016, Pages 27-36

  Haque, Tanvir ^a   Sasatomi, Eizaburo ^b   Hayashi, Paul H ^a  

^a Division of Gastroenterology and Hepatology   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Diagnosis; Drug induced liver injury; Epidemiology; Hepatotoxicity; Herbal and dietary supplements

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; CARBAMAZEPINE; EPHEDRA EXTRACT; GREEN TEA EXTRACT; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOLOGIC AGENT; ISONIAZID; KETOCONAZOLE; MINOCYCLINE; MUSCLE ENHANCER; NITROFURANTOIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFONAMIDE; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; VALPROIC ACID; TUMOR NECROSIS FACTOR;

ANAMNESIS; CLINICAL FEATURE; DIET SUPPLEMENTATION; HISTOPATHOLOGY; HUMAN; INCIDENCE; LIVER RESECTION; OUTCOME ASSESSMENT; PATTERN RECOGNITION; PHARMACOEPIDEMIOLOGY; PHENOTYPE; REVIEW; RISK FACTOR; TOXIC HEPATITIS; ADVERSE EFFECTS; AGE; ANTAGONISTS AND INHIBITORS; BIOPSY; CHEMICAL AND DRUG INDUCED LIVER INJURY; DIETARY SUPPLEMENT; LIVER; LIVER FUNCTION TEST; PATHOLOGY;

AGE FACTORS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICONVULSANTS; BIOPSY; CHEMICAL AND DRUG INDUCED LIVER INJURY; DIETARY SUPPLEMENTS; DRUGS, CHINESE HERBAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LIVER; LIVER FUNCTION TESTS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84957310533     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl15114     Document Type: Review

References (107)

1. Ostapowicz G, Fontana RJ, Schiødt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-954.
2. Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007;6:904-916.
3. Björnsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis 2014;34:115-122.
4. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36:451-455.
5. de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004;58:71-80.
6. Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol 2005;33:155-164.
7. Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastro-enterology 2013;144:1419-1425.e3.
8. Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepato-toxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005;128:116-123.
9. Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 1992;15:154-161.
10. Stock JG, Strunin L. Unexplained hepatitis following halothane. Anesthesiology 1985;63:424-439.
11. Lucena MI, Andrade RJ, Fernandez MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 2006;44:850-856.
12. Stricker BH, Blok AP, Claas FH, Van Parys GE, Desmet VJ. Hepatic injury associated with the use of nitrofurans: a clinicopath-ological study of 52 reported cases. Hepatology 1988;8:599-606.
13. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135: 1924-1934.e4.
14. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroen-terol 2014;109:950-966.
15. Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmaco-dynamic considerations in patients with liver disease: an update. Clin Pharmacokinet 1995;29:370-391.
16. Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis. A practical guide. Aliment Pharmacol Ther 2013;37:1132-1156.
17. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-952.
18. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-contain-ing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002;35:182-189.
19. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004;10:1018-1023.
20. Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009;49:2001-2009.
21. Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013;58:388-396.
22. Bénichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990;11:272-276.
23. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs: II. an original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331-1336.
24. Chitturi S, Farrell GC. Drug-induced liver disease. In: Schiff ER, Maddrey WC, Sorrell MF, eds. Schiff's diseases of the liver. 11th ed. Chichester: Wiley-Blackwell, 2012:703-783.
25. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169-176.
26. Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl 2007;13:953-955.
27. Ichai P, Duclos-Vallée JC, Guettier C, et al. Usefulness of cortico-steroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007;13:996-1003.
28. Danan G, Benichou C. Causality assessment of adverse reactions to drugs: I. a novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330.
29. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997;26:664-669.
30. Hayashi PH, Fontana RJ. Clinical features, diagnosis, and natural history of drug-induced liver injury. Semin Liver Dis 2014;34:134-144.
31. Rochon J, Protiva P, Seeff LB, et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008;48:1175-1183.
32. Hoofnagle JH, Serrano J, Knoben JE, Navarro VJ. LiverTox: a website on drug-induced liver injury. Hepatology 2013;57:873-874.
33. National Library of Medicine. LiverTox [Internet]. Bethesda: National Library of Medicine; c2015 [cited 2015 Jan 14]. Available from: http://www.LiverTox.nih.gov.
34. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmaco-epidemiol Drug Saf 2006;15:241-243.
35. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005;42:481-489.
36. Andrade RJ, Lucena MI, Fernández MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512-521.
37. Bahirwani R, Reddy KR. Drug-induced liver injury due to cancer chemotherapeutic agents. Semin Liver Dis 2014;34:162-171.
38. Hicks LA, Taylor TH Jr, Hunkler RJ. U.S. outpatient antibiotic prescribing, 2010. N Engl J Med 2013;368:1461-1462.
39. Larrey D, Vial T, Micaleff A, et al. Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut 1992;33:368-371.
40. García Rodríguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996;156:1327-1332.
41. Reddy KR, Brillant P, Schiff ER. Amoxicillin-clavulanate potassium-associated cholestasis. Gastroenterology 1989;96:1135-1141.
42. Richardet JP, Mallat A, Zafrani ES, Blazquez M, Bognel JC, Campillo B. Prolonged cholestasis with ductopenia after administration of amoxicillin/clavulanic acid. Dig Dis Sci 1999;44:1997-2000.
43. Eckstein RP, Dowsett JF, Lunzer MR. Flucloxacillin induced liver disease: histopathological findings at biopsy and autopsy. Pathology 1993;25:223-228.
44. Peker E, Cagan E, Dogan M. Ceftriaxone-induced toxic hepatitis. World J Gastroenterol 2009;15:2669-2671.
45. Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther 2011;89:911-914.
46. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepa-totoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008;23:192-202.
47. Sharma SK, Singla R, Sarda P, et al. Safety of 3 different reintro-duction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010;50:833-839.
48. Tahaoglu K, Atac G, Sevim T, et al. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2001;5:65-69.
49. Durand F, Bernuau J, Pessayre D, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or sub-fulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995;21:929-932.
50. Mainra RR, Card SE. Trimethoprim-sulfamethoxazole-associated hepatotoxicity: part of a hypersensitivity syndrome. Can J Clin Pharmacol 2003;10:175-178.
51. Yao F, Behling CA, Saab S, Li S, Hart M, Lyche KD. Trimethoprim-sulfamethoxazole-induced vanishing bile duct syndrome. Am J Gastroenterol 1997;92:167-169.
52. García Rodríguez LA, Duque A, Castellsague J, Pérez-Gutthann S, Stricker BH. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 1999;48:847-852.
53. Stricker BH, Blok AP, Bronkhorst FB, Van Parys GE, Desmet VJ. Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases. J Hepatol 1986;3:399-406.
54. Ikemoto H. A clinical study of fluconazole for the treatment of deep mycoses. Diagn Microbiol Infect Dis 1989;12(4 Suppl):239S-247S.
55. Fischer MA, Winkelmayer WC, Rubin RH, Avorn J. The hepa-totoxicity of antifungal medications in bone marrow transplant recipients. Clin Infect Dis 2005;41:301-307.
56. Núñez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010;52:1143-1155.
57. Surgers L, Lacombe K. Hepatoxicity of new antiretrovirals: a systematic review. Clin Res Hepatol Gastroenterol 2013;37:126-133.
58. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based anti-retroviral regimens with or without concurrent ritonavir. AIDS 2004;18:2277-2284.
59. Sulkowski MS. Drug-induced liver injury associated with antiret-roviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004;38 Suppl 2:S90-S97.
60. Eshki M, Allanore L, Musette P, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol 2009;145:67-72.
61. Mullick FG, Ishak KG. Hepatic injury associated with diphenylhy-dantoin therapy: a clinicopathologic study of 20 cases. Am J Clin Pathol 1980;74:442-452.
62. Zimmerman HJ, Ishak KG. Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology 1982;2:591-597.
63. Lacroix I, Lapeyre-Mestre M, Bagheri H, et al. Nonsteroidal anti-inflammatory drug-induced liver injury: a case-control study in primary care. Fundam Clin Pharmacol 2004;18:201-206.
64. Johnson AG, Day RO. The problems and pitfalls of NSAID therapy in the elderly (Part I). Drugs Aging 1991;1:130-143.
65. Manoukian AV, Carson JL. Nonsteroidal anti-inflammatory drug-induced hepatic disorders: incidence and prevention. Drug Saf 1996;15:64-71.
66. Riley TR 3rd, Smith JP. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series. Am J Gastroenterol 1998;93:1563-1565.
67. Andrade RJ, Lucena MI, García-Cortés M, García-Ruiz E, Fernán-dez-Bonilla E, Vázquez L. Chronic hepatitis C, ibuprofen, and liver damage. Am J Gastroenterol 2002;97:1854-1855.
68. Scully LJ, Clarke D, Barr RJ. Diclofenac induced hepatitis: 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 1993;38:744-751.
69. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastro-enterology 2007;132:272-281.
70. Maddrey WC, Maurath CJ, Verburg KM, Geis GS. The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. Am J Ther 2000;7:153-158.
71. El Hajj I, Malik SM, Alwakeel HR, Shaikh OS, Sasatomi E, Kandil HM. Celecoxib-induced cholestatic liver failure requiring ortho-topic liver transplantation. World J Gastroenterol 2009;15:3937-3939.
72. Tolman KG. Defining patient risks from expanded preventive therapies. Am J Cardiol 2000;85:15E-19E.
73. McKenney JM, Davidson MH, Jacobson TA, Guyton JR; National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006;97:89C-94C.
74. Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007;46:1453-1463.
75. Avins AL, Manos MM, Ackerson L, et al. Hepatic effects of lo-vastatin exposure in patients with liver disease: a retrospective cohort study. Drug Saf 2008;31:325-334.
76. Grimbert S, Pessayre D, Degott C, Benhamou JP. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin. Dig Dis Sci 1994;39:2032-2033.
77. Hartleb M, Rymarczyk G, Januszewski K. Acute cholestatic hepatitis associated with pravastatin. Am J Gastroenterol 1999;94: 1388-1390.
78. Pelli N, Setti M, Ceppa P, Toncini C, Indiveri F. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol 2003;15:921-924.
79. Tolman KG. The liver and lovastatin. Am J Cardiol 2002;89:1374-1380.
80. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoof-nagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015;61:703-711.
81. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatol-ogy 2009;50:661-662.
82. Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol 2013;11:558-564.e3.
83. Becker H, Willeke P, Domschke W, Gaubitz M. Etanercept tolerance in a patient with previous infliximab-induced hepatitis. Clin Rheumatol 2008;27:1597-1598.
84. Thiéfin G, Morelet A, Heurgué A, Diebold MD, Eschard JP. Inflix-imab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine 2008;75:737-739.
85. Parekh R, Kaur N. Liver injury secondary to anti-TNF-alpha therapy in inflammatory bowel disease: a case series and review of the literature. Case Rep Gastrointest Med 2014;2014:956463.
86. Bailey RL, Gahche JJ, Lentino CV, et al. Dietary supplement use in the United States, 2003-2006. J Nutr 2011;141:261-266.
87. Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology 2014;60:1399-1408.
88. Navarro VJ, Lucena MI. Hepatotoxicity induced by herbal and dietary supplements. Semin Liver Dis 2014;34:172-193.
89. Bunchorntavakul C, Reddy KR. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther 2013;37:3-17.
90. Skoulidis F, Alexander GJ, Davies SE. Ma huang associated acute liver failure requiring liver transplantation. Eur J Gastroenterol Hepatol 2005;17:581-584.
91. Neff GW, Reddy KR, Durazo FA, Meyer D, Marrero R, Kaplowitz N. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J Hepatol 2004; 41:1062-1064.
92. Food and Drug Administration (FDA). FDA issues regulation prohibiting sale of dietary supplements containing ephedrine alkaloids and reiterates its advice that consumers stop using these products [Internet]. Silver Spring: FDA; 2004 [cited 2015 Nov 9]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108242.htm.
93. Navarro VJ, Bonkovsky HL, Hwang SI, Vega M, Barnhart H, Serrano J. Catechins in dietary supplements and hepatotoxicity. Dig Dis Sci 2013;58:2682-2690.
94. Bonkovsky HL. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med 2006;144:68-71.
95. Javaid A, Bonkovsky HL. Hepatotoxicity due to extracts of Chinese green tea (Camellia sinensis): a growing concern. J Hepatol 2006;45:334-335.
96. Vanstraelen S, Rahier J, Geubel AP. Jaundice as a misadventure of a green tea (camellia sinensis) lover: a case report. Acta Gas-troenterol Belg 2008;71:409-412.
97. Dara L, Hewett J, Lim JK. Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. World J Gastroenterol 2008;14:6999-7004.
98. Singh V, Rudraraju M, Carey EJ, et al. Severe hepatotoxicity caused by a methasteron-containing performance-enhancing supplement. J Clin Gastroenterol 2009;43:287.
99. Martin DJ, Partridge BJ, Shields W. Hepatotoxicity associated with the dietary supplement N.O.-XPLODE. Ann Intern Med 2013;159:503-504.
100. Glober GA, Wilkerson JA. Biliary cirrhosis following the administration of methyltestosterone. JAMA 1968;204:170-173.
101. Westaby D, Portmann B, Williams R. Androgen related primary hepatic tumors in non-Fanconi patients. Cancer 1983;51:1947-1952.
102. Monshi MM, Faulkner L, Gibson A, et al. Human leukocyte antigen (HLA)-B∗57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 2013;57:727-739.
103. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486.
104. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002;166:916-919.
105. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1∗0101 and abrogated by low CD4 T-cell counts. AIDS 2005;19:97-99.
106. Urban TJ, Daly AK, Aithal GP. Genetic basis of drug-induced liver injury: present and future. Semin Liver Dis 2014;34:123-133.
107. Bamshad MJ, Ng SB, Bigham AW, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 2011; 12:745-755.